BioSpace News Archive

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 79,800 restricted stock units to five newly-hired employees.

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 23rd Annual Needham Virtual Healthcare Conference, on Monday, April 8, 2024, which includes a presentation beginning at 12:45 pm ET.

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023.

Acorda Therapeutics, Inc. announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET.

Biomea Fusion, Inc. announced that on April 1, 2024, the compensation committee of Biomea’s board of directors granted two new employees non-qualified stock options to purchase an aggregate of 6,500 shares of the Company’s common stock.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent operational highlights.

Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose and throat (ENT) surgical interventions.

ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update.

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying common warrants to purchase common stock.